Company profile: Allakos
1.1 - Company Overview
Company description
- Provider of therapeutic antibodies for allergy, inflammatory and proliferative diseases, including AK006, a humanized IgG1 monoclonal antibody targeting Siglec-6 to inhibit mast cell activation and reduce mast cell numbers via antibody-dependent cellular phagocytosis, and AK007, a humanized Siglec-10 antagonist that blocks ligand interaction to restore macrophage and dendritic cell anti-tumor activity and promote anti-tumor immunity.
Products and services
- Therapeutic Antibody Development: target-specific program develops therapeutic antibodies for allergy, inflammatory, and proliferative diseases, including Siglec-6 and Siglec-10 targets
- AK007: humanized antagonist antibody against Siglec-10 that blocks ligand interactions to restore macrophage and dendritic cell anti-tumor activity and promote anti-tumor immunity
- AK006: humanized IgG1 monoclonal antibody targeting Siglec-6, engineered to inhibit mast cell activation and reduce mast cell numbers via antibody-dependent cellular phagocytosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allakos
Telavant
HQ: United States
Website
- Description: Provider of novel medicines in development to assist patients suffering from inflammatory and fibrotic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telavant company profile →
Sucampo Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialized biopharmaceuticals addressing unmet medical needs, with marketed products AMITIZA for chronic constipation and IBS-C in adults and RESCULA in Japan for lowering intraocular pressure in glaucoma or ocular hypertension, and a late-stage pipeline including VTS-270 for Niemann-Pick Disease Type C and CPP-1X/sulindac for Familial Adenomatous Polyposis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sucampo Pharmaceuticals company profile →
Gossamer Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development of novel and differentiated therapeutic products, including seralutinib for pulmonary arterial hypertension in Phase 3 clinical trials, and offering clinical trials and an expanded access program for investigational medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gossamer Bio company profile →
Moderna
HQ: United States
Website
- Description: Provider of mRNA-based vaccines and therapeutics, including SPIKEVAX (FDA-approved COVID-19 vaccine), mRESVIA (RSV vaccine for older adults), and pipeline candidates mRNA-1283 (next-gen COVID, Phase 3), mRNA-1010 (flu, Phase 3), mRNA-1647 (CMV, Phase 3), and mRNA-4157 (individualized neoantigen cancer therapy, in collaboration with Merck).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Moderna company profile →
ADMA Biologics
HQ: United States
Website
- Description: Provider of plasma-based biologics, including ASCENIV IVIG for primary immunodeficiency disease (PIDD) and other immune-compromised conditions; BIVIGAM IVIG for primary humoral immunodeficiency (PI); Nabi-HB hyperimmune globulin to prevent hepatitis B infection following exposure; and ADMA BioCenters, a network of plasma collection centers supplying high-quality plasma for immunoglobulin manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADMA Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allakos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allakos
2.2 - Growth funds investing in similar companies to Allakos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allakos
4.2 - Public trading comparable groups for Allakos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →